拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02592 拨康视云-B

劳动节休市 04-30 16:08:13

1.480

-0.110

-6.92%

最高1.670	最低1.460	成交量65.35万
今开1.590	昨收1.590	日振幅13.21%
总市值12.61亿	流通市值12.61亿	总股本8.52亿
成交额99.91万	换手率0.08%	流通股本8.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":1.48,"timestamp":1777536493006,"preClose":1.59,"halted":0,"volume":653500,"delay":0,"changeRate":-0.06918238993710697,"floatShares":852000000,"shares":852000000,"eps":-0.8069792033838562,"marketStatus":"劳动节休市","change":-0.11,"latestTime":"04-30 16:08:13","open":1.59,"high":1.67,"low":1.46,"amount":999120,"amplitude":0.132075,"askPrice":1.48,"askSize":39500,"bidPrice":1.47,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-4.8486272666745,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.59,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":0.4265387376552519,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"2631686436","title":"拨康视云-B(02592)：美国药管局已完成对CBT-199的安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2631686436","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631686436?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:41","pubTimestamp":1777538474,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，本公司于美利坚合众国(美国)特拉华州注册成立的全资附属公司 ADS Therapeutics LLC ，已完成有关于2025年12月12日向美国食品及药物管理局提交的CBT-199新药临床试验申请的审查期。美国药管局已完成对新药临床试验申请的安全性审查，而美国药管局的结论为本公司可推进拟议的临床研究。本公司认为，由于美国药管局已完成对CBT-199的安全性审查，标志着CBT-199临床开发的关键里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","02592","BK4090","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1107086204","title":"拨康视云-B新药CBT-199获FDA安全审查通过 临床试验获准推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1107086204","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107086204?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:38","pubTimestamp":1777538296,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已完成对拨康视云-B旗下创新药物CBT-199的新药临床试验申请（IND）的安全性评估。此次审查的顺利通过，意味着该药物已获准进入下一阶段的临床研究。\n此次安全审查的通过为CBT-199的临床开发路径清除了关键监管障碍。根据流程，制药企业可在获得FDA安全性认可后，正式启动针对候选药物的临床阶段研究。\n这一进展标志着拨康视云-B在创新药研发领域迈出重要一步。随着临床试验的推进，CBT-199的治疗潜力将得到进一步验证，为后续研发工作奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124358329","title":"拨康视云-B（02592）完成基金赎回 48.0百万港元到账，年化回报约2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124358329","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124358329?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:46","pubTimestamp":1776861971,"startTime":"0","endTime":"0","summary":"拨康视云-B4月22日披露，已按董事会决议完成此前所持基金的全部赎回。公司共收回赎回款项约48.0百万港元，并实现收益约0.88百万港元，对应年化回报率约2.53%。\\n\\n此次赎回旨在降低不合规影响，保证所得款项用途符合规定。该基金注册于开曼群岛，为受当地金融管理局监管的豁免有限公司，资产管理规模逾1亿美元，持有人超过10名，且无单一投资者持股超过10%。基金普通合伙人的董事兼最终实益拥有人为Saadeddine Hanane，其与拨康视云-B及其关联方均保持独立。\\n\\n截至公告日，拨康视云-B董事会由3名执行董事、3名非执行董事及3名独立非执行董事组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107056212","title":"拨康视云-B全额赎回基金，获资4800万港元，录得88万港元收益，年化回报率达2.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107056212","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107056212?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:43","pubTimestamp":1776861795,"startTime":"0","endTime":"0","summary":"拨康视云-B宣布完成基金全额赎回操作，成功收回4800万港元资金。本次赎回为集团带来88万港元的投资收益，经计算年化回报率达到2.53%。此次交易体现了公司资金管理的高效运作，为股东创造了稳健的价值回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625193462","title":"拨康视云-B(02592)发行178.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625193462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625193462?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:35","pubTimestamp":1775558156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，于2026年4月3日，根据2023年股权激励计划配发及发行178.5万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164294550","title":"拨康视云-B：4月3日配发发行178.50万股股份，占已发行股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164294550","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164294550?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:12","pubTimestamp":1775556760,"startTime":"0","endTime":"0","summary":"拨康视云-B(股票代码：02592)于2026年4月7日发布公告，披露公司在2026年4月3日根据2023年股权激励计划配发及发行178.50万股普通股，占发行前已发行股本850,122,081股的约0.21%。每股发售价为0港元。上述发行完成后，公司已发行股本增至851,907,081股，库藏股数量维持为0股。\n公告同时确认，本次股份发行已获董事会正式授权并遵守香港联合交易所有限公司证券上市规则及相关法律程序。公告由公司秘书冯雅芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176722646","title":"拨康视云-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1176722646","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176722646?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:21","pubTimestamp":1775017268,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc.于2026年4月1日发布截至2026年3月31日的股份变动月报表。公告显示，公司3月期间未有新增发行、购回或注销股份，整体股本维持稳定。截至3月31日，公司实际已发行股份合计850,122,081股，与上月期末持平，库藏股份为0股。公司在公告中声明，所有股份和激励计划均已获得董事会正式授权，并遵守香港联交所《上市规则》及相关法律规定。至此，公司本月股本结构未发生实质性变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328973","title":"拨康视云-B(02592)发布年度业绩 净亏损6766万美元 同比收窄31.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328973","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623328973?lang=zh_cn&edition=full","pubTime":"2026-03-31 01:39","pubTimestamp":1774892378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布截至2025年12月31日止年度年度业绩，该集团研发开支6680.2万美元，同比扩大76.04%;净亏损6766万美元，同比收窄31.75%;每股基本亏损0.10美元。公告称，待监管机构批准后，我们预计将在约四年内(即2030年前)于美国市场推出CBT-001。同时，我们将评估商业化方案，同时最大限度地发挥我们专有技术及资产，作为我们投资组合的一部分。鉴于翼状胬肉及结膜充血患者数目众多，且市场竞争有限，我们预期CBT-001上市后将有巨大市场机会及可观收益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"拨康视云-B(02592)发布年度业绩 净亏损6766万美元 同比收窄31.75%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420690","title":"港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420690","media":"智通财经","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620420690?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:35","pubTimestamp":1773974109,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B跌超6%，低见1.82港元刷新上市以来新低。在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4090","02592","VXUS","BK1161","CBT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244220","title":"拨康视云-B(02592)：撤回CBT-009新药临床试验申请 重新评估临床开发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244220?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:05","pubTimestamp":1773918320,"startTime":"0","endTime":"0","summary":"在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。待完成相关补充研究或调整临床试验方案后，公司将根据情况再次与药审中心进行临床试验申请前咨询会议或重新提交临床试验申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4090","BK1161","02592","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291559","title":"拨康视云-B(02592)股东将股票存入建设亚洲 存仓市值1.94亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291559","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620291559?lang=zh_cn&edition=full","pubTime":"2026-03-19 08:09","pubTimestamp":1773878951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，3月18日，拨康视云-B(02592)股东将股票存入建设亚洲，存仓市值1.94亿港元，占比11.23%。2月16日，拨康视云发布公告，公司于美利坚合众国(美国)特拉华州注册成立的全资附属公司 ADS Therapeutics LLC (ADS USA)，已完成有关于2025年12月12日向美国食品及药物管理局(美国药管局)提交的CBT-199(一种由本集团开发的潜在同类最佳眼科候选药物)新药临床试验申请(新药临床试验申请)的审查期。由于美国药管局未发出任何临床试验暂停令，新药临床试验申请现已生效，临床试验被认定为可安全推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618613540","title":"每日卖空追踪 | 拨康视云-B 03月12日卖空量成交6500股，卖空比例为1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618613540","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618613540?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304233,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间03月12日，跌3.72%，卖空量成交6500股，较上一交易日增加225%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163443a463751d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163443a463751d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618892060","title":"拨康视云-B盘中异动 下午盘大幅下挫5.26%报2.160港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618892060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618892060?lang=zh_cn&edition=full","pubTime":"2026-03-11 13:56","pubTimestamp":1773208581,"startTime":"0","endTime":"0","summary":"2026年03月11日下午盘13时56分，拨康视云-B股票出现波动，股价大幅下挫5.26%。截至发稿，该股报2.160港元/股，成交量9.75万股，换手率0.01%，振幅4.39%。资金方面，该股资金流入1.336万港元，流出20.149万港元。拨康视云-B股票所在的生物技术行业中，整体跌幅为1.97%。其相关个股中，中慧生物-B、迈博药业-B、翰思艾泰-B涨幅较大，振幅较大的相关个股有迈博药业-B、中慧生物-B、映恩生物-B，振幅分别为25.58%、20.00%、11.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311135621a460538a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311135621a460538a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618676352","title":"拨康视云-B盘中异动 大幅下跌6.88%报2.030港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618676352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618676352?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:40","pubTimestamp":1773020430,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时40分，拨康视云-B股票出现异动，股价急速下跌6.88%。截至发稿，该股报2.030港元/股，成交量500股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出1015港元。拨康视云-B股票所在的生物技术行业中，整体跌幅为3.19%。其相关个股中，科济药业-B、维立志博-B、愉悦集团涨幅较大，振幅较大的相关个股有科济药业-B、派格生物医药-B、维立志博-B，振幅分别为30.36%、15.64%、12.63%。该公司拥有两款核心产品 CBT-001和CBT-009,均为自主研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030909403097aa9b2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030909403097aa9b2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616326302","title":"拨康视云-B盘中异动 早盘大幅跳水5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616326302","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616326302?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:16","pubTimestamp":1772504216,"startTime":"0","endTime":"0","summary":"2026年03月03日早盘10时16分，拨康视云-B股票出现波动，股价急速下挫5.88%。截至发稿，该股报1.920港元/股，成交量12.15万股，换手率0.01%，振幅6.37%。拨康视云-B股票所在的生物技术行业中，整体跌幅为2.22%。其相关个股中，科笛-B、华领医药-B、轩竹生物-B涨幅较大，振幅较大的相关个股有旺山旺水-B、和誉-B、银诺医药-B，振幅分别为17.31%、10.77%、8.32%。拨康视云-B公司简介：Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司,从事开发各种治疗方法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303101656a444561d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303101656a444561d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616935147","title":"每日卖空追踪 | 拨康视云-B 03月02日卖空量成交2.1万股，卖空比例为2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616935147","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616935147?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440235,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间03月02日，跌8.52%，卖空量成交2.1万股，较上一交易日增加75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163509a4415196&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163509a4415196&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131140470","title":"Cloudbreak Pharma（02592）2026年2月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131140470","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131140470?lang=zh_cn&edition=full","pubTime":"2026-03-02 15:01","pubTimestamp":1772434918,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc.于2026年3月2日发布截至2026年2月28日的证券变动月报。报告显示，本月公司已发行股本及库藏股数量均未发生增减。截至2月28日，已发行股份数为850,122,081股，库藏股份为0股，均与上月底保持一致，期间未有新增发行或购回注销活动。本月内，各相关计划项下均无新股发行、期权行使或库藏股转让行为，潜在可发行或转让股份数量保持不变。公告由公司秘书冯雅芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616230351","title":"拨康视云-B盘中异动 股价大跌5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616230351","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616230351?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:14","pubTimestamp":1772417685,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘10时14分，拨康视云-B股票出现异动，股价快速下跌5.83%。截至发稿，该股报2.100港元/股，成交量15.15万股，换手率0.02%，振幅5.83%。资金方面，该股资金流入8.1195万港元，流出23.631万港元。拨康视云-B股票所在的生物技术行业中，整体跌幅为2.97%。拨康视云-B公司简介：Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司,从事开发各种治疗方法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302101445a72f6a02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302101445a72f6a02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614931864","title":"每日卖空追踪 | 拨康视云-B 02月27日卖空量成交1000股，卖空比例为0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614931864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614931864?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:30","pubTimestamp":1772181033,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间02月27日，跌1.33%，卖空量成交1000股，较上一交易日减少98.45%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163439a725f46e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163439a725f46e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614078953","title":"每日卖空追踪 | 拨康视云-B 02月26日卖空量成交2.05万股，卖空比例为7.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614078953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614078953?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:30","pubTimestamp":1772094632,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间02月26日，涨0.44%，卖空量成交2.05万股，较上一交易日减少41.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163445a7219b90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163445a7219b90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":-0.0692},{"period":"1month","weight":-0.1591},{"period":"3month","weight":-0.3959},{"period":"6month","weight":-0.6858},{"period":"1year","weight":-0.8535},{"period":"ytd","weight":-0.7154}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司，从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009，均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉（一种良性增生性眼表疾病），已在美国和中国启动III期多区域临床试验（MRCT）。该公司的核心产品CBT-009用于治疗青少年近视（5至19岁儿童和青少年的近视），已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段，包括另外两种临床阶段候选药物，即CBT-006和CBT-004，以及四种临床前阶段候选药物，即CBT-007、CBT-199、CBT-145和CBT-011。","exchange":"SEHK","name":"拨康视云-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拨康视云-B,02592,拨康视云-B股票,拨康视云-B股票老虎,拨康视云-B股票老虎国际,拨康视云-B行情,拨康视云-B股票行情,拨康视云-B股价,拨康视云-B股市,拨康视云-B股票价格,拨康视云-B股票交易,拨康视云-B股票购买,拨康视云-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}